Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 1;80(11):1136-1137.
doi: 10.1001/jamaneurol.2023.3539.

Synaptic Oligomers and Glial Cells in Alzheimer Disease

Affiliations
Editorial

Synaptic Oligomers and Glial Cells in Alzheimer Disease

Lea Tenenholz Grinberg. JAMA Neurol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Sims JR, Zimmer JA, Evans CD, et al.; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023.13239 - DOI - PMC - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. doi:10.1056/NEJMoa2212948 - DOI - PubMed
    1. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–172. doi:10.1038/s41582-020-00435-v - DOI - PubMed
    1. Taddei RN, Perbet R, de Gerando AM, et al. Correlation of tau oligomer–containing synapses engulfed by microglia and astrocytes with cognition in Alzheimer disease. JAMA Neurol. Published online October 9, 2023. doi:10.1001/jamaneurol.2023.3530 - DOI - PMC - PubMed
    1. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90)(15):695–703. doi:10.1212/WNL.0000000000005303 - DOI - PMC - PubMed

Substances